US 8,921,377 B2 · Substituted 5-fluoro-1H-pyrazolopyridines and their use

Substituted 5-fluoro-1H-pyrazolopyridines and their use

AssigneeBayer Intellectual Property GmbH

InventorsMarkus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer

Life of this patent

Estimating the term…

Abstract

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Claims12

Dependent claims

A method of treatment of heart failure in humans and animals by administration of an effective amount of at least one compound of formula (I)

in which
R1 represents hydrogen or (C1-C4)-alkyl,
where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
or a salt thereof.

1 more element

A method of treatment of heart failure comprising administering to a human or animal an effective amount of a pharmaceutical composition, comprising a compound of formula (I) and an inert, non-toxic, pharmaceutically suitable excipient, wherein the compound of formula I is:

in which
R1 represents hydrogen or (C1-C4)-alkyl,
where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
or a salt thereof.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

13/851,373Filed 27 Mar 2013 · continuation

Priority

DE 10 2010 021 63726 May 2010

Published

US 2013/0237551 A112 Sep 2013

Granted

30 Dec 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 7/00
Drugs for disorders of the blood or the extracellular fluid
A61P 7/02
Drugs for disorders of the blood or the extracellular fluid: antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Family

Application13/111,856Parent of this continuation · filed 19 May 2011

US 2013/0237551 A1Pre-grant publication · published 12 Sep 2013

US 8,420,656 B2Parent of this continuation

US 2012/0022084 A1Published application

US 8,921,377 B2This patent

From the US filing history. Foreign family members aren’t listed.